JARED T RYE NP
Prescription History 1457596413
Nurse Practitioner in Nampa, ID

NPI Status: Active since December 04, 2008

Contact Information

1510 12TH AVENUE RD
STE 200
NAMPA, ID
ZIP 83686
Phone: (208) 302-0600
Fax: (208) 302-0755

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JARED T RYE NP, an active Nurse Practitioner specialist practicing in Nampa, ID. Our medical registry currently tracks 31 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,653 documented patient claims. Among these therapy options, the most frequently utilized medication is Trulicity, which accounts for 190 claims alone.


Alcohol Prep Pads

Generic Formulation: Alcohol Antiseptic PadsSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 550
ID State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply744
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $120.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.46

State Avg Cost Per Claim

$4.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Baqsimi

Generic Formulation: GlucagonSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 142
ID State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.6
Peer Average Days Supply288
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,941.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$303.23

State Avg Cost Per Claim

$515.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

Therapeutic Applications

This medication is the same as your body's own glucagon, a natural substance that raises blood sugar by causing the body to release sugar stored in the liver. It is used to treat very low blood sugar (hypoglycemia) that may cause you to need help from others. Make sure a family member or caregiver knows where you keep this medication and how to use it before you need their help.

Basaglar Kwikpen U-100

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 44
30-Day Fills 91.0
Days Supply 2,702
ID State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply966
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 83.3% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,594.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$718.06

State Avg Cost Per Claim

$416.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Droplet Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 46.0
Days Supply 1,315
ID State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills41.1
Peer Average Days Supply1,212
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,845.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$92.29

State Avg Cost Per Claim

$68.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Easy Touch Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 27.3
Days Supply 675
ID State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills22.8
Peer Average Days Supply582
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,387.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.34

State Avg Cost Per Claim

$50.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Farxiga

Generic Formulation: Dapagliflozin PropanediolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 29
30-Day Fills 59.0
Days Supply 1,770
ID State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills52.5
Peer Average Days Supply1,548
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,018.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,173.06

State Avg Cost Per Claim

$930.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This medication is also used in people with type 2 diabetes and heart disease to lower the risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sugar by your kidneys. Dapagliflozin is also used to treat kidney disease and heart failure. It may help you live longer and lower your risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sodium by your kidneys.

Fiasp Flextouch

Generic Formulation: Insulin Aspart (Niacinamide)Specialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 19.6
Days Supply 587
ID State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply563
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,947.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,328.99

State Avg Cost Per Claim

$597.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.

Glimepiride

Generic Formulation: GlimepirideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 34.0
Days Supply 1,020
ID State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills85.8
Peer Average Days Supply2,563
Conservative Utilization

This provider writes prescriptions for this formulation 41.2% less frequently than the standard regional baseline metric for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $151.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.57

State Avg Cost Per Claim

$13.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Alkaloids derived from TYRAMINE combined with 3,4-dihydroxybenzaldehyde via a norbelladine pathway, including GALANTAMINE, lycorine and crinine. They are found in the AMARYLLIDACEAE plant family.

Therapeutic Applications

Glimepiride is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. It may also be used with other diabetes medications. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Glimepiride belongs to the class of drugs known as sulfonylureas. It lowers blood sugar by causing the release of your body's natural insulin.

Glipizide

Generic Formulation: GlipizideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 26
30-Day Fills 67.3
Days Supply 2,020
ID State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,584
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $531.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.45

State Avg Cost Per Claim

$7.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

Therapeutic Applications

Glipizide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. It may also be used with other diabetes medications. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Glipizide belongs to the class of drugs known as sulfonylureas. It lowers blood sugar by causing the release of your body's natural insulin.

Glipizide Er

Generic Formulation: GlipizideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 27.7
Days Supply 830
ID State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills67.6
Peer Average Days Supply2,017
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.01

State Avg Cost Per Claim

$18.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

Therapeutic Applications

Glipizide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. It may also be used with other diabetes medications. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Glipizide belongs to the class of drugs known as sulfonylureas. It lowers blood sugar by causing the release of your body's natural insulin.

Humalog Kwikpen U-100

Generic Formulation: Insulin LisproSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 30
30-Day Fills 62.4
Days Supply 1,850
ID State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills43.8
Peer Average Days Supply1,234
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,268.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$942.29

State Avg Cost Per Claim

$945.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Therapeutic Applications

Insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin lispro is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin lispro starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. Insulin lispro may also be used with other oral diabetes medications (such as sulfonylureas like glyburide or glipizide).

Insulin Lispro Kwikpen U-100

Generic Formulation: Insulin LisproSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 52
30-Day Fills 84.3
Days Supply 2,529
ID State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills39.0
Peer Average Days Supply923
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 79.3% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,495.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$336.45

State Avg Cost Per Claim

$174.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Therapeutic Applications

Insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin lispro is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin lispro starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. Insulin lispro may also be used with other oral diabetes medications (such as sulfonylureas like glyburide or glipizide).

Januvia

Generic Formulation: Sitagliptin PhosphateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 41.7
Days Supply 1,250
ID State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills40.6
Peer Average Days Supply1,154
Conservative Utilization

This provider writes prescriptions for this formulation 34.8% less frequently than the standard regional baseline metric for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,464.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,497.62

State Avg Cost Per Claim

$883.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.

Therapeutic Applications

Sitagliptin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Sitagliptin is a diabetes drug that works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes.

Jardiance

Generic Formulation: EmpagliflozinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 66
30-Day Fills 110.3
Days Supply 3,310
ID State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills58.5
Peer Average Days Supply1,722
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 106.3% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,763.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,011.56

State Avg Cost Per Claim

$1,034.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Empagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Empagliflozin is also used in patients with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Empagliflozin works by increasing the removal of sugar by your kidneys. Empagliflozin is also used to treat heart failure. It may help you live longer and lower your risk of going to the hospital for heart failure. Empagliflozin works by increasing the removal of sodium by your kidneys.

Lantus

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 26
30-Day Fills 45.5
Days Supply 1,281
ID State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply873
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,707.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$719.53

State Avg Cost Per Claim

$680.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Lantus Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 146
30-Day Fills 271.3
Days Supply 8,043
ID State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply1,590
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 356.3% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $113,366.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$776.48

State Avg Cost Per Claim

$625.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Levemir Flexpen

Generic Formulation: Insulin DetemirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 52
30-Day Fills 93.1
Days Supply 2,602
ID State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$1,010.82

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin detemir is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin detemir is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin detemir may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs (such as metformin, exenatide).

Metformin Hcl

Generic Formulation: Metformin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 111
30-Day Fills 299.0
Days Supply 8,947
ID State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills166.1
Peer Average Days Supply4,951
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.6% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,296.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.68

State Avg Cost Per Claim

$7.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

Therapeutic Applications

Metformin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin works by helping to restore your body's proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that your stomach/intestines absorb.

Metformin Hcl Er

Generic Formulation: Metformin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 88
30-Day Fills 238.0
Days Supply 7,140
ID State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills139.5
Peer Average Days Supply4,166
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 51.7% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,163.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.22

State Avg Cost Per Claim

$10.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

Therapeutic Applications

Metformin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin works by helping to restore your body's proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that your stomach/intestines absorb.

Nano 2nd Gen Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 73
30-Day Fills 107.4
Days Supply 2,920
ID State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,254
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 265.0% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,671.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$91.39

State Avg Cost Per Claim

$92.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Novolog

Generic Formulation: Insulin AspartSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 15.6
Days Supply 420
ID State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills37.7
Peer Average Days Supply1,048
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,763.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$396.93

State Avg Cost Per Claim

$970.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.

Therapeutic Applications

Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.

Novolog Flexpen

Generic Formulation: Insulin AspartSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 144
30-Day Fills 282.3
Days Supply 8,339
ID State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills42.4
Peer Average Days Supply1,182
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 433.3% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $171,725.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,192.54

State Avg Cost Per Claim

$861.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.

Therapeutic Applications

Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.

Ozempic

Generic Formulation: SemaglutideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 166
30-Day Fills 254.2
Days Supply 7,397
ID State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills47.1
Peer Average Days Supply1,365
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 388.2% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $238,066.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,434.14

State Avg Cost Per Claim

$1,233.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 44
30-Day Fills 72.4
Days Supply 2,142
ID State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills36.6
Peer Average Days Supply1,058
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 120.0% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,524.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.65

State Avg Cost Per Claim

$27.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Toujeo Max Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 47
30-Day Fills 72.5
Days Supply 2,023
ID State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply1,056
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 161.1% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $76,326.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,623.96

State Avg Cost Per Claim

$1,310.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Toujeo Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 74
30-Day Fills 153.1
Days Supply 4,511
ID State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills41.9
Peer Average Days Supply1,170
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 196.0% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $73,413.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$992.07

State Avg Cost Per Claim

$715.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Tresiba Flextouch U-100

Generic Formulation: Insulin DegludecSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 30
30-Day Fills 56.9
Days Supply 1,693
ID State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills45.6
Peer Average Days Supply1,310
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,940.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$931.33

State Avg Cost Per Claim

$668.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

Tresiba Flextouch U-200

Generic Formulation: Insulin DegludecSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 26
30-Day Fills 66.1
Days Supply 1,965
ID State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills48.0
Peer Average Days Supply1,378
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,250.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$932.72

State Avg Cost Per Claim

$1,155.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

Trulicity

Generic Formulation: DulaglutideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 190
30-Day Fills 280.2
Days Supply 8,132
ID State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills52.6
Peer Average Days Supply1,515
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 413.5% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $274,180.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,443.06

State Avg Cost Per Claim

$1,318.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dulaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. This medication is also used to lessen the risk of a major cardiovascular event (such as heart attack or stroke) in people who already have, or are at high risk for heart/blood vessel disease. Dulaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and by decreasing the amount of sugar your liver makes. Dulaglutide is not a substitute for insulin if you need insulin treatment.

Ultra-Fine Mini Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 28
30-Day Fills 70.5
Days Supply 2,110
ID State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills41.4
Peer Average Days Supply1,216
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 55.6% higher than the standard regional baseline profile for ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,133.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$111.91

State Avg Cost Per Claim

$83.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Ultra-Fine Nano Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.8
Days Supply 435
ID State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills34.5
Peer Average Days Supply1,013
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,144.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$88.07

State Avg Cost Per Claim

$90.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JARED T RYE NP provides transparency into local medical care patterns within Nampa, ID.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.